Cipla is currently trading at Rs. 1211.55, up by 7.50 points or 0.62% from its previous closing of Rs. 1204.05 on the BSE.
The scrip opened at Rs. 1204.50 and has touched a high and low of Rs. 1211.95 and Rs. 1201.85 respectively. So far 5373 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1277.55 on 10-Aug-2023 and a 52 week low of Rs. 852.00 on 22-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1219.15 and Rs. 1186.65 respectively. The current market cap of the company is Rs. 97702.52 crore.
The promoters holding in the company stood at 33.47%, while Institutions and Non-Institutions held 49.85% and 16.67% respectively.
Cipla has received approval from board of directors to transfer Generics Business Undertaking as a going concern on a slump sale basis to Cipla Pharma and Life Sciences (CPLS), a wholly owned subsidiary of the Company. Effective date for completion of transfer to CPLS would be end of business hours of December 31, 2023, or such other date mutually agreed between the parties. The consideration to be received from such sale will be Rs 350 crore. The Board of Directors of the company at its meeting held on November 06, 2023 have inter alia, approved the same.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: